Litigation Details for GRUNENTHAL GMBH v. HIKMA PHARMACEUTICALS USA INC. (D.N.J. 2026)

GRUNENTHAL GMBH v. HIKMA PHARMACEUTICALS USA INC. (D.N.J. 2026)

Docket		Date Filed	2026-02-02
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Esther Salas
Jury Demand	Plaintiff	Referred To	Jose R. Almonte
Patents	11,344,512; 8,536,130
Attorneys	J. BRUGH LOWER
Link to Docket	External link to docket

Details for GRUNENTHAL GMBH v. HIKMA PHARMACEUTICALS USA INC. (D.N.J. 2026)

Date Filed	Document No.	Description	Snippet	Link To Document
2026-02-02				External link to document

Litigation summary and analysis for: GRUNENTHAL GMBH v. HIKMA PHARMACEUTICALS USA INC. (D.N.J. 2026)

Last updated: June 17, 2026

GRUNENTHAL v. HIKMA (2:26-cv-00999): Litigation Summary, Case Posture, and Patent/Exclusivity Analysis

Executive summary: The case Grünenthal GmbH v. Hikma Pharmaceuticals USA Inc. (Docket No. 2:26-cv-00999) is a recently filed federal patent litigation matter (filed in 2026) in which Grünenthal accuses Hikma of infringing one or more Orange Book-listed patents tied to Grünenthal’s marketed product. As of the available record for this docket, a complete, element-by-element infringement and defense breakdown cannot be produced without the complaint, asserted patent list, and schedule of filings.

What is the case timeline for Grunenthal GmbH v. Hikma Pharmaceuticals USA Inc. (2:26-cv-00999)?

Answer (timeline): File date: 2026 (case number indicates 2026 filing). No further case dates, claim construction schedule, trial date, or settlement milestones are available in the information provided.

Key docket milestones that typically matter in Paragraph IV and Hatch-Waxman suits

• Complaint filing date and asserted patent list
• Hikma’s responsive pleadings (answer, affirmative defenses)
• Rule 12 motions (if any)
• Markman briefing schedule (if claim construction is requested)
• Scheduling order (expert deadlines, discovery cutoff)
• Any dismissal without prejudice or amended complaint activity
• Settlement agreement docket entries (often sealed)
• Final judgment or consent judgments (if any)

What patents are asserted in Grunenthal v. Hikma (2:26-cv-00999)?

Answer (asserted patents): Not determinable from the information provided. The asserted patent numbers, publication/application data, and their legal status (Orange Book listing, expiration, PTA, litigation stay posture) are not included.

How asserted patents are usually structured in Grünenthal-origin cases

When Grünenthal sues under Hatch-Waxman, the asserted estate typically covers:

• Composition-of-matter patents (active ingredient or specific crystalline forms)
• Formulation patents (solid state, polymorphs, coating systems, excipients)
• Method-of-use patents (dosing regimens, patient subsets, therapeutic indications)
• Process/manufacturing patents (crystallization, drying, impurity control)

What claims are being litigated: composition, formulation, or method-of-use in 2:26-cv-00999?

Answer (claim type): Not determinable from the information provided.

Typical claim mapping in Hikma-facing Orange Book suits

Hikma’s generic development often triggers disputes around:

• Whether the proposed ANDA product infringes the specific claim language of the listed patent(s)
• Whether the patent(s) are invalid for anticipation/obviousness or unenforceable for inequitable conduct
• Whether infringement is indirect (inducement/contributory) where labeling drives use

What is the Orange Book status of the Grünenthal product at issue in 2:26-cv-00999?

Answer (Orange Book status): Not determinable from the information provided. Orange Book listing data requires the NDA/ANDA product, drug strength, dosage form, and the listed patents.

What to extract from Orange Book to evaluate exclusivity

• Listed drug (reference listed drug, or RLD)
• Patent numbers and patent expiry dates
• Whether patents are tied to drug substance, drug product, or method of use
• Whether the suit is expected to be tied to a Paragraph IV notice
• Exclusivity type: NCE, 505(b)(2) exclusivity, pediatric exclusivity, or orphan exclusivity

When does Grünenthal’s exclusivity or key patent protection expire for this case?

Answer (exclusivity/patent expiry): Not determinable from the information provided.

How to read the exclusivity clock in Hatch-Waxman litigation

• Patent expiry date(s) for the asserted patents
• Any pediatric exclusivity extensions (6 months) that shift the effective barrier
• Any licensed settlements that convert the statutory exclusivity into an agreed launch date

Has Hikma filed a Paragraph IV certification in this lawsuit?

Answer (Paragraph IV posture): Not determinable from the information provided. Paragraph IV status depends on:

• ANDA number and listed certification(s)
• Notice of Paragraph IV patent challenge dates
• Whether the suit is a first-filing or follow-on filing

How strong is Grünenthal’s patent estate in this litigation (2:26-cv-00999)?

Answer (strength assessment): Not determinable from the information provided. Strength requires at minimum:

• Asserted patent claim set
• Whether there is controlling prior art or claim construction risk
• File history context
• PTAB activity or other litigations on the same patents

What “strength” usually means in this fact pattern

• Claim scope clarity (Markman risk)
• Known invalidity threats in other cases
• Whether the same patent has survived prior challenges
• Whether the asserted claims are narrow and directly mapped to the generic’s design

What defenses does Hikma likely raise, and how do courts treat them in similar suits?

Answer (likely defenses): Not determinable from the information provided. A proper defense analysis needs the answer, invalidity contentions, and any inequitable conduct/unenforceability pleading.

Common defense buckets in Hikma-type ANDA suits

• Non-infringement (no literal infringement; no DOE)
• Invalidity (35 USC 102/103; lack of written description or enablement; indefiniteness)
• Unenforceability (inequitable conduct)
• Nonstatutory obviousness-type double patenting (if relevant)
• Improper patent listing or jurisdictional defects (rare but possible)

What is the current litigation posture: motions, discovery, and any settlement activity?

Answer (posture): Not determinable from the information provided. A posture read requires docket entries such as motion filings, scheduling orders, and any settlement-related entries.

What signals a settlement vs. trial track

• Joint motion to stay or dismiss after mediation
• Sealed settlement agreement entries
• Consent judgments tied to an agreed launch date
• Amended complaint narrowing asserted patents

Which FDA pathway and ANDA product is involved in 2:26-cv-00999?

Answer (FDA pathway/ANDA): Not determinable from the information provided. Without the ANDA number and product label listing, it is not possible to connect the patents to the proposed generic.

What to confirm for launch risk

• ANDA submission date and certification type
• Proposed formulation and strength
• Whether Hikma is attempting to design around specific formulation claims
• Whether the generic triggers a new bioequivalence waiver vs. full BE study

How does the case compare with other recent Grunenthal versus generic challenges?

Answer (comparative analysis): Not determinable from the information provided. A meaningful comparison requires identifying:

• The specific Grünenthal product(s) and patent estate involved
• Prior litigations (same patents, same generic developer)
• Consistent outcomes in claim construction or settlement terms

Key Takeaways

• Docket identified: Grunenthal GmbH v. Hikma Pharmaceuticals USA Inc., 2:26-cv-00999.
• Litigation type implied: Hatch-Waxman-style patent infringement posture is consistent with Grünenthal’s typical Orange Book enforcement, but the asserted patents, ANDA details, and current docket status are not present in the provided information.
• Business decision impact: Without the asserted patent list and docket events, launch/competition risk cannot be mapped to specific exclusivity dates or design-around feasibility.

FAQs

1. What does docket number 2:26-cv-00999 indicate about filing year and jurisdiction?
2. How do you determine which Orange Book patents are asserted once the complaint is filed?
3. What documentation in a typical ANDA case links a Paragraph IV notice to a lawsuit docket?
4. What court steps control pace in Hatch-Waxman suits after the answer is filed?
5. How can claim construction outcomes shift settlement leverage in formulation patent disputes?

References (APA)

1. Grunenthal GmbH v. Hikma Pharmaceuticals USA Inc., Case No. 2:26-cv-00999 (U.S. District Court, 2026).